These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 19740349

  • 1. Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity.
    Ding Y, Seow SV, Huang CH, Liew LM, Lim YC, Kuo IC, Chua KY.
    Immunology; 2009 Sep; 128(1 Suppl):e881-94. PubMed ID: 19740349
    [Abstract] [Full Text] [Related]

  • 2. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model.
    Kim TG, Kim CH, Won EH, Bae SM, Ahn WS, Park JB, Sin JI.
    Immunology; 2004 May; 112(1):117-25. PubMed ID: 15096191
    [Abstract] [Full Text] [Related]

  • 3. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
    Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham GP, Cannon MJ.
    J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
    [Abstract] [Full Text] [Related]

  • 4. Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression.
    Sin JI.
    Immunology; 2009 Sep; 128(1 Suppl):e707-17. PubMed ID: 19740332
    [Abstract] [Full Text] [Related]

  • 5. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
    Yang Y, Che Y, Zhao Y, Wang X.
    Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
    [Abstract] [Full Text] [Related]

  • 6. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.
    Clin Cancer Res; 2008 Jan 01; 14(1):178-87. PubMed ID: 18172269
    [Abstract] [Full Text] [Related]

  • 7. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
    Hallez S, Simon P, Maudoux F, Doyen J, Noël JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost AC, Hubert P, Gerday C, Burny A, Boniver J, Foidart JM, Delvenne P, Jacobs N.
    Cancer Immunol Immunother; 2004 Jul 01; 53(7):642-50. PubMed ID: 14985860
    [Abstract] [Full Text] [Related]

  • 8. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.
    Lamikanra A, Pan ZK, Isaacs SN, Wu TC, Paterson Y.
    J Virol; 2001 Oct 01; 75(20):9654-64. PubMed ID: 11559797
    [Abstract] [Full Text] [Related]

  • 9. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.
    Kim MS, Sin JI.
    Immunology; 2005 Oct 01; 116(2):255-66. PubMed ID: 16162274
    [Abstract] [Full Text] [Related]

  • 10. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    J Virol; 2009 Jul 01; 83(13):6779-89. PubMed ID: 19386711
    [Abstract] [Full Text] [Related]

  • 11. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses.
    Kim D, Monie A, He L, Tsai YC, Hung CF, Wu TC.
    Gene Ther; 2008 May 01; 15(9):677-87. PubMed ID: 18273057
    [Abstract] [Full Text] [Related]

  • 12. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.
    Lee SY, Kang TH, Knoff J, Huang Z, Soong RS, Alvarez RD, Hung CF, Wu TC.
    Cancer Immunol Immunother; 2013 Jul 01; 62(7):1175-85. PubMed ID: 23615841
    [Abstract] [Full Text] [Related]

  • 13. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model.
    Ahn WS, Bae SM, Kim TY, Kim TG, Lee JM, Namkoong SE, Kim CK, Sin JI.
    Hum Gene Ther; 2003 Oct 10; 14(15):1389-99. PubMed ID: 14577920
    [Abstract] [Full Text] [Related]

  • 14. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA.
    Clin Exp Immunol; 2000 Aug 10; 121(2):216-25. PubMed ID: 10931134
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with Candida skin test reagent as an adjuvant in C57BL/6 mice.
    Wang X, Che Y, Chen B, Zhang Y, Nakagawa M, Wang X.
    Int Immunopharmacol; 2018 Mar 10; 56():249-260. PubMed ID: 29414659
    [Abstract] [Full Text] [Related]

  • 16. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
    Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJ.
    J Immunol; 2002 Jul 01; 169(1):350-8. PubMed ID: 12077264
    [Abstract] [Full Text] [Related]

  • 17. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M, Momot M, Goubier A, Gonindard C, Leung-Theung-Long S, Misseri Y, Bissery MC.
    Vaccine; 2017 Mar 13; 35(11):1509-1516. PubMed ID: 28196735
    [Abstract] [Full Text] [Related]

  • 18. Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein.
    Liu H, Wu BH, Rowse GJ, Emtage PC.
    Clin Vaccine Immunol; 2007 Aug 13; 14(8):1013-23. PubMed ID: 17596433
    [Abstract] [Full Text] [Related]

  • 19. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies.
    Kim TW, Hung CF, Boyd D, Juang J, He L, Kim JW, Hardwick JM, Wu TC.
    J Immunol; 2003 Sep 15; 171(6):2970-6. PubMed ID: 12960321
    [Abstract] [Full Text] [Related]

  • 20. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D.
    Diniz MO, Lasaro MO, Ertl HC, Ferreira LC.
    Clin Vaccine Immunol; 2010 Oct 15; 17(10):1576-83. PubMed ID: 20739505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.